

GCHP Medi-Cal Clinical Guidelines Collagenase Clostridium Histolyticum (XiaflexTM)

PA Criteria	Criteria Details						
Covered Uses (FDA approved indication)	<ul style="list-style-type: none">Treatment of adults with Dupuytren contracture with a palpable cord.Treatment of adult with Peyronie disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.						
Exclusion Criteria	Treatment of Peyronie plaques that involve the penile urethra.						
Required Medical Information	<p>For <u>Dupuytren contracture</u> and ALL of the following:</p> <ul style="list-style-type: none">Palpable cord present at metacarpophalangeal (MP) joint or proximal interphalangeal (PIP) joint.No surgical treatment of cord during prior 90 days. <p>For <u>Peyronie disease</u> and ALL of the following:</p> <ul style="list-style-type: none">Curvature deformity of 30 degrees or greater at start of therapy.Palpable plaque.No plaque involvement of penile urethra.Treating provider is certified with Xiaflex Risk Evaluation and Mitigation Strategy (REMS) program.						
Age Restriction	18 years of age and older.						
Prescriber Restrictions	<p>Prescribed by or in conjunction with healthcare provider experienced in injection procedure of the hand for the treatment of Dupuytren’s contracture.</p> <p>Prescribed by or in conjunction with a urologist experienced in injection procedure for the treatment of Peyronie disease.</p>						
Coverage Duration	Six months						
Other Criteria / Information	<table><tr><th>HCPCS</th><th>Description</th><th>Dosing, Units</th></tr><tr><td>J0775</td><td>Injection, Collagenase, clostridium histolyticum, 0.01mg (Xiaflex™),</td><td><u>Dupuytren contracture</u> 0.58mg intralesionally per cord affecting a MP joint or PIP joint. Up to two injections per hand may be used during a treatment; two palpable cord affecting two joints or one palpable cord affecting two joints in the same finger may be injected at two locations during a treatment. Other palpable cords with contractures of MP or PIP joints may be injected at other treatment visits ~four weeks apart.</td></tr></table>	HCPCS	Description	Dosing, Units	J0775	Injection, Collagenase, clostridium histolyticum, 0.01mg (Xiaflex™),	<u>Dupuytren contracture</u> 0.58mg intralesionally per cord affecting a MP joint or PIP joint. Up to two injections per hand may be used during a treatment; two palpable cord affecting two joints or one palpable cord affecting two joints in the same finger may be injected at two locations during a treatment. Other palpable cords with contractures of MP or PIP joints may be injected at other treatment visits ~four weeks apart.
HCPCS	Description	Dosing, Units					
J0775	Injection, Collagenase, clostridium histolyticum, 0.01mg (Xiaflex™),	<u>Dupuytren contracture</u> 0.58mg intralesionally per cord affecting a MP joint or PIP joint. Up to two injections per hand may be used during a treatment; two palpable cord affecting two joints or one palpable cord affecting two joints in the same finger may be injected at two locations during a treatment. Other palpable cords with contractures of MP or PIP joints may be injected at other treatment visits ~four weeks apart.					



			<p><u>Peyronie disease</u> 0.58mg intralesionally into a Peyronie plaque; repeat injection one to three days later. Administer a second treatment cycle (two 0.58 mg injections and a penile modeling procedure) in ~six weeks if needed. If more than one plaque is present, inject into the plaque causing the curvature deformity. Maximum dose: four treatment cycles (a total of eight injection procedures and four penile modeling procedures). The safety of more than one treatment course (i.e., four treatment cycles) is not known.</p>
--	--	--	---

STATUS	DATE REVISED	REVIEW DATE	APPROVED / REVIEWED BY	EFFECTIVE DATE
Created	8/5/2024	8/5/2024	Yoonhee Kim, Clinical Programs Pharmacist	N/A
Approved	N/A	8/14/2024	Pharmacy & Therapeutics (P&T) Committee	3/1/2025